Tagged with Research

basic research Manuel Díaz-Rubio, honorary president of Spain’s Royal Academy of Medicine, traces the history of Spain’s medical community over the last few decades, and emphasizes the importance of the pharmaceutical industry to the careers of doctors and physicians across the world.   You were head of Hospital San Carlos’ gastroenterology unit…

innovation Joaquin Poch, president of the Royal Academy of Medicine of Spain, outlines the Academy’s history and current initiatives.   What are the objectives of the Royal Academy of Medicine and what are your own personal objectives as president? In order to answer this question we have to go back to…

clinical research Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the encouraging progress of Malaysia as an attractive place for trials since clinical research was placed under the healthcare NKEA National…

basic research The executive coordinator of GACTEC maps the current level of science and technology in Argentina and outlines the country’s ambitions in this area, which is to have an impact on innovation at the international level.     When was the cabinet was founded and what exactly is its role? The Scientific Technological Cabinet…

technology transfer Joan Guinovart, director of the Institute for Research in Biomedicine in Barcelona (IRB Barcelona), discusses the Institute’s unique interdisciplinary characteristics and emphasises the need for Spain to foster technology transfer as a means to further innovation.   As a means of introduction, could you briefly outline your background and IRB?…

diagnostics Life Length was founded through the CNIO (Spanish National Cancer Research Center) combined with the support of the Botín Foundation, Matlin Associates and Dr. Maria Blasco’s work in telomeres. Stephen J. Matlin, CEO of Life Length, discusses the potential of the company’s diagnostic test to become a standard biomarker for…

cancer Manuel Hidalgo, director of the Centro Integral Oncológico Clara Campal (CIOCC), discusses the expansion of the private sector of hospitals in Spain and the latest developments that CIOCC has taken in the area of personalized medicine.   How has the quality of healthcare in Spain changed or evolved over the…

Pfizer “Although Pfizer is today one of the major contributors to Investigator-Initiated Research in Portugal in very important areas like inflammation, vaccines and rare diseases, it is also important that we reverse the trends observed concerning our levels of local investment in R&D, namely through the attraction of more clinical trials…

Gubelkian Jose Pereira Leal, Group Leader Head of the Bioinformatics Unit at Instituto Gulbenkian de Ciencia, discusses the institute’s unique selling point, stating that, “researchers will continue to come and stay here based on the excellence of research” that the country, and institute in particular, are currently experiencing.   Since its…

scienfitic output João Lobo Antunes, Founder of Institute of Molecular Medicine (IMM), Portugal gives his insights into Portugal’s strengths in science and technology, as well as his ambitions to grow IMM into one of the world’s leading institutes for genomics.   How would you rate Portugal’s scientific output nationwide? The scientific development…

Basic Research Despite declining investments by big pharma in recent years, Canada has created a number of innovative ways to incentivize R&D throughout its vast geography. “Science powers commerce,” Canadian Prime Minister Stephen Harper remarked in 2010. In those three words, the prime minister summarizes a massive effort by various stakeholders to…

UAE Mohammed Zafrullah, VP & General Manager of GlaxoSmithKline (GSK) Pharmaceuticals, argues that the UAE, despite recent turmoil in the rest of the Middle East, is the perfect emerging country to do build a business in due to the many opportunities for innovation and growth.   To have a successful business,…